Horizon Therapeutics competitors, on the record

Who Horizon Therapeutics names

In its own words

1. AstraZeneca plc, Genentech/Chugai Pharmaceuticals Co., Ltd.

   Word for word“UPLIZNA faces competition from eculizumab, marketed as Soliris ® by AstraZeneca plc, and satralizumab, marketed as Enspryng TM by Genentech/Chugai Pharmaceuticals Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd., each for the treatment of patients with NMOSD.” 10-K for 2022

2. Mylan N.V., Orphan Europe SARL

   Word for word“Cystagon, an immediate-release cysteamine bitartrate capsule, is an older-generation systemic cystine-depleting therapy for cystinosis in the United States marketed by Mylan N.V., and by Orphan Europe SARL in markets outside of the United States.” 10-K for 2022

3. Recordati S.p.A

   Word for word“We are also aware that Recordati S.p.A (formerly known as Orphan Europe SARL), or Recordati, received FDA approval in January 2021 for carglumic acid for the treatment of acute hyperammonemia due to propionic acidemia or methylmalonic acidemia.” 10-K for 2022

4. Selecta Biosciences Inc.

   Word for word“However, a number of competitors have medicines in clinical trials, including Selecta Biosciences Inc., or Selecta, which has initiated a Phase 3 clinical program of a candidate for the treatment of chronic refractory gout.” 10-K for 2022

Read from Horizon Therapeutics’s annual reports (10-K for 2022, 10-K for 2021, 10-K for 2020) and the financial data it files with the SEC, as of 2023-03-01. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.